	US 11,752,198 B2
	GLP-1 compositions and uses thereof
Eva Horn Moeller, Alleroed (DK); Michael Duelund Soerensen, Soeborg (DK); and Joakim Lundqvist, Malmoe (SE)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Dec. 8, 2020, as Appl. No. 17/115,773.
Application 17/115,773 is a continuation of application No. 16/774,666, filed on Jan. 28, 2020, granted, now 10,888,605.
Application 16/774,666 is a continuation of application No. PCT/EP2018/072835, filed on Aug. 24, 2018.
Claims priority of application No. 17187676 (EP), filed on Aug. 24, 2017.
Prior Publication US 2021/0085755 A1, Mar. 25, 2021
Int. Cl. A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01)

CPC A61K 38/26 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01)]

9 Claims

1. A liquid pharmaceutical composition comprising:

semaglutide;

wherein said composition

does not contain phenol;

is for parenteral administration;

is an aqueous solution comprising at least 60% (w/w) water; or

further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent; and

wherein the semaglutide is in the range of 0.01 mg/ml-10.0 mg/ml; and

wherein the pH of the composition is in between 7.0 and 7.8;

wherein the liquid pharmaceutical composition exhibits improved chemical and/or physical stability as compared to a liquid pharmaceutical composition that contains phenol.